Source:Journal of Allergy and Clinical Immunology, Volume 139, Issue 5
Author(s): Mylène S. Veilleux, Neil H. Shear
Biologic agents are important therapeutic options for treating multiple moderate-to-severe cutaneous diseases. Monoclonal antibodies already in use or under investigation are targeted for psoriasis, atopic dermatitis, melanoma, hidradenitis suppurativa, and pemphigus vulgaris.
http://ift.tt/2pIplAX
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου